EFTR - eFFECTOR Therapeutics, Inc.
Previous close
0.1891
-11.761 -6,219.408%
Share volume: 0
Last Updated: Tue 02 Jul 2024 08:03:49 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.25%
PREVIOUS CLOSE
CHG
CHG%
$11.95
-11.76
-98.42%
View ratios
| Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | |
| Report Date | 2022-05-10 | 2022-08-09 | 2022-11-07 | 2023-03-08 | 2023-05-09 | 2023-08-08 | 2023-11-13 | |
| Assets | ||||||||
| Total Assets | 49.495 M | 43.471 M | 36.651 M | 29.077 M | 21.928 M | 26.889 M | 20.161 M | |
| Current Assets | 48.339 M | 42.283 M | 35.521 M | 28.014 M | 20.894 M | 25.975 M | 19.282 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 2.633 M | 1.245 M | 2.565 M | 1.704 M | 1.887 M | 956.000 K | 1.503 M | |
| Short Term Investments | 2.633 M | 1.245 M | 2.565 M | 1.704 M | 1.887 M | 956.000 K | 1.503 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 45.706 M | 41.038 M | 32.956 M | 26.310 M | 19.007 M | 25.019 M | 17.779 M | |
| Total Non-current Assets | 1.156 M | 1.188 M | 1.130 M | 1.063 M | 1.034 M | 914.000 K | 879.000 K | |
| Property Plant Equipment | 149.000 K | 242.000 K | 246.000 K | 241.000 K | 214.000 K | 216.000 K | 244.000 K | |
| Other Assets | 854.000 K | 807.000 K | 759.000 K | 711.000 K | 723.000 K | 615.000 K | 567.000 K | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | ||||||||
| Total Liabilities and shareholders’ equity | 49.495 M | 43.471 M | 36.651 M | 29.077 M | 21.928 M | 26.889 M | 20.161 M | |
| Total liabilities | 24.261 M | 23.848 M | 25.091 M | 25.181 M | 26.741 M | 24.314 M | 24.127 M | |
| Total current liabilities | 2.630 M | 23.585 M | 24.968 M | 25.075 M | 26.652 M | 23.759 M | 23.588 M | |
| Accounts Payable | 294.000 K | 1.204 M | 1.214 M | 1.486 M | 3.794 M | 1.451 M | 1.136 M | |
| Other liabilities | 1.606 M | 169.000 K | 46.000 K | 46.000 K | 46.000 K | 530.000 K | 533.000 K | |
| Current long term debt | 0.000 | 20.011 M | 20.085 M | 20.161 M | 20.237 M | 20.316 M | 20.399 M | |
| Long term debt | 19.916 M | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 1.606 M | 169.000 K | 46.000 K | 46.000 K | 46.000 K | 530.000 K | 533.000 K | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 25.234 M | 19.623 M | 11.560 M | 3.896 M | -4.813 M | 2.575 M | -3.966 M | |
| Common stock | 40.848 M | 41.119 M | 41.172 M | 41.580 M | 42.001 M | 47.829 M | 61.768 M | |
| Retained earnings | -117.832 M | -124.747 M | -134.306 M | -143.566 M | -153.580 M | -161.944 M | -170.247 M |